Proteomic evaluation of Pip6a-PMO treatment for myotonic dystrophy type 1

Proteomic evaluation of Pip6a-PMO treatment for myotonic dystrophy type 1

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Holland, A, Varela, M, Hazell, G, Klein, A, Arzumanov, A, Raz, R, Gait, M, Furling, D, Wood, M
Μορφή:	Conference item
Γλώσσα:	English
Έκδοση:	Elsevier 2018

Παρόμοια τεκμήρια

PPMO's as therapeutic modulators for myotonic dystrophy type 1
ανά: Holland, A, κ.ά.
Έκδοση: (2018)

Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment.
ανά: Betts, C, κ.ά.
Έκδοση: (2012)

Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice
ανά: Klein, AF, κ.ά.
Έκδοση: (2019)

Application of antisense conjugates for the treatment of myotonic dystrophy type 1
ανά: Stoodley, J, κ.ά.
Έκδοση: (2023)

Peptide-conjugated PMOs for the treatment of myotonic dystrophy
ανά: Stoodley, J, κ.ά.
Έκδοση: (2022)

NOVEL CELL PENETRATING PEPTIDES FOR SKELETAL AND CARDIAC MUSCLE DELIVERY OF PMO ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
ανά: Hammond, S, κ.ά.
Έκδοση: (2011)

Proteomic analysis of the function of DMPK, the myotonic dystrophy protein kinase
ανά: Luciano, Brenda Sierra, 1965-
Έκδοση: (2005)

New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). The International Myotonic Dystrophy Consortium (IDMC).
ανά: Ashizawa, T, κ.ά.
Έκδοση: (2000)

The myotonic dystrophies: diagnosis and management.
ανά: Turner, C, κ.ά.
Έκδοση: (2010)

Molecular genetics of myotonic dystrophy.
ανά: Barnes, P, κ.ά.
Έκδοση: (1993)

Application of CRISPR-Cas9-mediated genome editing for the treatment of myotonic dystrophy type 1
ανά: Marsh, S, κ.ά.
Έκδοση: (2020)

Hearing impairment in patients with myotonic dystrophy type 2
ανά: van Vliet, J, κ.ά.
Έκδοση: (2018)

Alternative isoform regulation in myotonic dystrophy
ανά: Wang, Eric T. (Eric Tzy-shi)
Έκδοση: (2012)

Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model
ανά: Overby, SJ, κ.ά.
Έκδοση: (2022)

Myotonic dystrophy: diagnosis, management and new therapies.
ανά: Turner, C, κ.ά.
Έκδοση: (2014)

Modafinil for excessive daytime sleepiness in myotonic dystrophy type 1--the patients' perspective.
ανά: Hilton-Jones, D, κ.ά.
Έκδοση: (2012)

Modafinil for excessive daytime sleepiness in myotonic dystrophy type 1 - The patients' perspective
ανά: Hilton-Jones, D, κ.ά.
Έκδοση: (2012)

Childhood-onset form of myotonic dystrophy type 1 and autism spectrum disorder: Is there comorbidity?
ανά: Angeard, N, κ.ά.
Έκδοση: (2017)

Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy
ανά: Cerro-Herreros, E, κ.ά.
Έκδοση: (2021)

Myotonic dystrophy--forgotten aspects of an often neglected condition.
ανά: Hilton-Jones, D
Έκδοση: (1997)

Clinical and molecular aspects of the myotonic dystrophies: a review.
ανά: Machuca-Tzili, L, κ.ά.
Έκδοση: (2005)

Myotonic dystrophy: practical issues relating to assessment of strength.
ανά: Whittaker, R, κ.ά.
Έκδοση: (2006)

Choroidal new vessels in type 1 myotonic dystrophy-related macular dystrophy respond to anti-VEGF therapy.
ανά: Zinkernagel, MS, κ.ά.
Έκδοση: (2012)

Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy.
ανά: Talbot, K, κ.ά.
Έκδοση: (2003)

Late-onset cytoplasmic body myopathy resembling myotonic dystrophy.
ανά: Morris, H, κ.ά.
Έκδοση: (1999)

Three cases of androgen-dependent disease associated with myotonic dystrophy.
ανά: Cooper, S, κ.ά.
Έκδοση: (2003)

Positive effect of modafinil on daytime somnolence on patients with Myotonic Dystrophy
ανά: Talbot, K, κ.ά.
Έκδοση: (2002)

Preclinical development of antisense conjugates for the treatment of myotonic dystrophy 1
ανά: Stoodley, J
Έκδοση: (2024)

Downregulation of the Glial GLT1 glutamate transporter and purkinje cell dysfunction in a mouse model of myotonic dystrophy
ανά: Sicot, G, κ.ά.
Έκδοση: (2017)

Advancing the potential of peptide-PMO compounds in exon skipping therapy for DMD
ανά: Godfrey, C, κ.ά.
Έκδοση: (2012)

A randomised controlled trial of modafinil for treatment of daytime somnolence in myotonic dystrophy
ανά: Talbot, K, κ.ά.
Έκδοση: (2003)

Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice.
ανά: Yin, H, κ.ά.
Έκδοση: (2011)

Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice
ανά: Yin, H, κ.ά.
Έκδοση: (2011)

Using digital technologies to engage with medical research: views of myotonic dystrophy patients in Japan
ανά: Coathup, V, κ.ά.
Έκδοση: (2016)

Dose-Dependent Regulation of Alternative Splicing by MBNL Proteins Reveals Biomarkers for Myotonic Dystrophy
ανά: Wagner, Stacey D., κ.ά.
Έκδοση: (2017)

Incorrect diagnosis of myotonic dystrophy and its potential consequences revealed by subsequent direct genetic analysis.
ανά: Barnes, P, κ.ά.
Έκδοση: (1994)

Relationship between muscle impairments, postural stability, and gait parameters assessed with lower-trunk accelerometry in myotonic dystrophy type 1
ανά: Bachasson, D, κ.ά.
Έκδοση: (2016)

DMPK and myotonic dystrophy : effects of CTG trinucleotide expansion upon DMPK and their contribution to DM pathogenesis
ανά: Davis, Brigid Michele, 1967-
Έκδοση: (2009)

The PMO theory of organic chemistry /
ανά: 291716 Dewar, Michael James Steuart, κ.ά.
Έκδοση: (1975)

Does cytosine-thymine-guanine (CTG) expansion size predict cardiac events and electrocardiographic progression in myotonic dystrophy?
ανά: Clarke, N, κ.ά.
Έκδοση: (2001)